While the UK legalised medicinal weed back in 2018, it’s been incredibly difficult to get it on an NHS prescription.
Those who did obtain it on the national health service were likely to be struggling with severe forms of epilepsy, vomiting caused by chemotherapy or spasms caused by multiple sclerosis.
But now, Boots will become the first UK high street pharmacy to privately prescribe cannabis flower or oil to patients over 25.
Through its new online SureLeaf service, clinicians will be able to give cannabis to people struggling with things like chronic pain, insomnia or even anxiety.
Pain conditions, which may mean you’re eligible for the treatments, include chronic primary and neuropathic pain, fibromyalgia, chronic back or neck pain, osteoarthritis and rheumatoid arthritis, to name a few.
For women suffering with endometriosis-related pelvic pain, it could also be a treatment option, as well as for people who suffer with chronic migraines.
Look beyond the headlines
Get a curated list of the most important stories of the weekend every Sunday from our weekend editor Jess Austin.
Look beyond the headlines with exclusive articles, emotive interviews and must-read explainers from our expert team of reporters across news, lifestyle and entertainment.
It comes with certain stipulations, though. Patients will need to have tried other traditional forms of treatment for their conditions first, and there will be underlying health conditions that disqualify you from being eligible for a prescription.
These include things like psychosis or schizophrenia, bipolar disorder, liver disease or heart problems.
Thorrun Govind, former chair of the Royal College of Pharmacy, tells Metro that, for patients who haven’t responded to conventional treatments, medicinal cannabis could be ‘worth exploring’.
‘There isn’t one universal eligibility checklist for every cannabis-based medicine,’ Thorrun explains. ‘It depends on the patient’s circumstances, and the clinical judgement of the prescriber.’
If your clinician approves your prescription in a video consultation, it will be for a period of 28 days, with the lowest dosage costing you just under £40.
‘Cannabis-based medicines are controlled drugs and prescribing needs to be undertaken responsibly with proper assessment, monitoring and follow up,’ Thorrun adds.
‘But this development highlights the changing landscape of pharmacy and the role of community pharmacy in expanding access to healthcare.’
The side effects of medical cannabis
As with any treatment, there can be side effects when taking medicinal weed.
‘Cannabis contains several active compounds including THC and CBD, which can have different effects on the body,’ Thorrun explains. ‘Depending on the formulation, cannabis-based medicines may help some patients manage pain, improve sleep or alleviate certain symptoms.
‘However, just because something is derived from a plant does not mean it is automatically safe.’
Cannabis-containing products can cause dizziness and drowsiness, as well as impaired concentration, according to the pharmacist.
Things like a loss of appetite, nausea and diarrhoea, can also occur. It can impact your mood, too, including causing behavioural changes, feeling high, or on the opposite end of the spectrum, causing paranoia or suicidal thoughts.
It can also affect how other medicines work, according to the NHS.
Why is Boots prescribing cannabis a big deal?
It’s important to note that medical cannabis can be privately accessed in the UK already, however these are at dedicated private clinics like Curaleaf Clinic or Releaf UK.
Boots will bring these private prescriptions into the mainstream. Its new SureLeaf service is a specialist doctor-led medical cannabis service for people living with the aforementioned conditions.
It comes after Boots was taken over by Canadian company Whittington Investments, the holding company for the Weston family.
Canada liberalised access to medicinal cannabis in 2001, with its legal recreational market being set up in 2018.
Jamie Kerruish, chief healthcare officer for Boots shared his statement with Metro: ‘At Boots, we’re committed to making healthcare more accessible and helping people find the right support for their individual needs.
‘Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.’
It adds that SureLeaf will give eligible patients the chance to consider cannabis treatment alongside clinical expertise and ‘robust ongoing care’.
‘Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life,’ it adds.
Thorrun tells Metro that she’s also supportive of patients having access to this treatment, as long as they treat it as a medicine, rather than ‘a risk-free alternative or lifestyle product’.
Do you have a story you’d like to share? Get in touch by emailing MetroLifestyleTeam@metro.co.uk


Bengali (Bangladesh) ·
English (United States) ·